17-(3-pyridyl)androsta-5,16-dien-3-one: a steroidal inhibitor of cytochrome P450(17alpha)/C17-20 lyase; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 196941 |
| CHEMBL ID | 132778 |
| SCHEMBL ID | 1961409 |
| MeSH ID | M0237230 |
| Synonym |
|---|
| cb 7627 |
| CHEMBL132778 , |
| (8r,9s,10r,13s,14s)-10,13-dimethyl-17-pyridin-3-yl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthren-3-one |
| z2l6xs2r7h , |
| androsta-4,16-dien-3-one, 17-(3-pyridinyl)- |
| unii-z2l6xs2r7h |
| cb7627 |
| 154229-21-7 |
| cb-7627 |
| 17-(3-pyridyl)androsta-5,16-dien-3-one |
| 17-(3-pyridinyl)-androsta-4,16-diene-3-one |
| SCHEMBL1961409 |
| 17-(3-pyridyl)androsta-4,16-dien-3-one |
| GYJZZAJJENTSTP-NHFPKVKZSA-N |
| AKOS028109269 |
| Q30647364 |
| 17-(3-pyridinyl)-androsta-4,16-dien-3-one |
| bdbm50216168 |
| delta4-abiraterone |
| DTXSID90934961 |
| d4-abiraterone |
| HY-109619 |
| CS-0033729 |
| o4-abiraterone |
| abiraterone d4a metabolite |
| abiraterone (d4a) |
| (8r,9s,10r,13s,14s)-10,13-dimethyl-17-(pyridin-3-yl)-6,7,8,9,10,11,12,13,14,15-decahydro-1h-cyclopenta[a]phenanthren-3(2h)-one |
| MS-25350 |
| (8r,9s,10r,13s,14s)-10,13-dimethyl-17-(pyridin-3-yl)-1,2,6,7,8,9,10,11,12,13,14,15-dodecahydro-3h-cyclopenta[a]phenanthren-3-one |
| u7p , |
| (8alpha)-17-(pyridin-3-yl)androsta-4,16-dien-3-one |
| 17-(3-pyridinyl)androsta-4,16-dien-3-one |
| .delta.4-abiraterone |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Steroid 17-alpha-hydroxylase/17,20 lyase | Homo sapiens (human) | IC50 (µMol) | 0.0081 | 0.0020 | 0.9818 | 4.7300 | AID1342321; AID1375969 |
| Steroid 21-hydroxylase | Homo sapiens (human) | IC50 (µMol) | 0.0007 | 0.0007 | 2.3543 | 9.0100 | AID1375970 |
| 3-oxo-5-alpha-steroid 4-dehydrogenase 1 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 10.0000 | 0.0042 | 7.4680 | 21.1000 | AID207299 |
| 3-oxo-5-alpha-steroid 4-dehydrogenase 2 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 10.0000 | 0.0003 | 7.3294 | 21.1000 | AID207299 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| endoplasmic reticulum | Steroid 17-alpha-hydroxylase/17,20 lyase | Homo sapiens (human) |
| endoplasmic reticulum membrane | Steroid 17-alpha-hydroxylase/17,20 lyase | Homo sapiens (human) |
| axon | Steroid 17-alpha-hydroxylase/17,20 lyase | Homo sapiens (human) |
| neuronal cell body | Steroid 17-alpha-hydroxylase/17,20 lyase | Homo sapiens (human) |
| endoplasmic reticulum membrane | Steroid 21-hydroxylase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID207299 | Compound was tested for the inhibitory activity against Steroid 5-alpha-reductase in rat | 1998 | Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5 | Structure activity relationship study of known inhibitors of the enzyme 5 alpha-reductase (5AR). |
| AID1375971 | Selectivity ratio of IC50 for C-terminal His-tagged recombinant human CYP21A2deltaH mutant to IC50 for C-terminal His-tagged recombinant human CYP17A1delta19H mutant | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2. |
| AID1375970 | Inhibition of C-terminal His-tagged recombinant human CYP21A2deltaH mutant expressed in Escherichia coli DH5alpha assessed as decrease in progesterone hydroxylation preincubated for 3 mins followed by NADPH addition measured after 10 mins in presence of c | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2. |
| AID1375969 | Inhibition of C-terminal His-tagged recombinant human CYP17A1delta19H mutant expressed in Escherichia coli DH5alpha assessed as decrease in progesterone hydroxylation preincubated for 3 mins followed by NADPH addition measured after 10 mins in presence of | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.13) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||